|
|
 |
|
Viewing report
|
|
|
|
U.S. Market for In-Vitro Diagnostics 2011 (Immunochemistry, Molecular Diagnostics, Blood Donor Screening, Hemostasis, Hematology and Point-Of-Care Testing) (Executive Summary)
iData Research, Sep 2011, Pages: 9
By 2017, the U.S. in vitro diagnostic market is expected to approach $10 billion. The market segments covered in the U.S. Markets for In Vitro Diagnostics 2011 include:
- Immunochemistry,
-- Immunochemistry Analyzer
-- Immunology Diagnostic
-- Chemistry Diagnostics
-- Automated Urinalysis Instrument
- Molecular Diagnostics
-- Molecular Diagnostics Reagent
-- Molecular Diagnostics Instrument
- Hemostasis
-- Hemostasis Analyzer
-- Hemostasis Reagent
- Hematology
-- Hematology Analyzer Market
-- Hematology Reagent
- Blood Donor Screening
-- Blood Screening Analyzer
-- Blood Screening Assay Kit
- Point-of-Care Testing
-- Blood Gas Testing
-- Urinalysis Testing
-- Blood Glucose Testing
In 2010, the U.S. in vitro diagnostics market experienced significant growth due to the introduction of new Food and Drug Administration (FDA) approved assays. That year, many technologies were well established and equipment markets were saturated. However, innovation, demand for testing and development of new assays will drive market growth.
Within the in vitro diagnostics market, companies such as Siemens, Roche Diagnostics, Abbott Diagnostics and Beckman Coulter lead the market, among many others. This report provides a comprehensive and detailed analysis of market revenues by device type, market forecasts through 2017, unit sales, average selling prices, market drivers and limiters and a detailed competitive analysis, including manufacturer market shares and product portfolios.
This is an executive summary only, the full-report is also available for purchase.
Also available
U.S. Market for In-Vitro Diagnostics 2011 (Immunochemistry, Molecular Diagnostics, Blood Donor Screening, Hemostasis, Hematology and Point-Of-Care Testing)
|
|
|
|
